#####
Currently, there are 77.09M common shares owned by the public and among those 62.53M shares have been available to trade.
#####
#####
#####
The company’s stock has a 5-day price change of -77.38% and -68.00% over the past three months. REPL shares are trading -72.12% year to date (YTD), with the 12-month market performance down to -76.84% lower. It has a 12-month low price of $6.44 and touched a high of $17.00 over the same period. REPL has an average intraday trading volume of 1.57 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -72.30%, -70.28%, and -74.55% respectively.
Institutional ownership of Replimune Group Inc (NASDAQ: REPL) shares accounts for 93.95% of the company’s 77.09M shares outstanding.
It has a market capitalization of $216.23M and a beta (3y monthly) value of 0.70. The earnings-per-share (ttm) stands at -$3.21. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.06% over the week and 8.09% over the month.
Earnings per share for the fiscal year are expected to increase by 8.57%, and 39.19% over the next financial year. EPS should grow at an annualized rate of 24.14% over the next five years, compared to -14.85% over the past 5-year period.
#####
Looking at the support for the REPL, a number of firms have released research notes about the stock. Wedbush stated their Neutral rating for the stock in a research note on July 22, 2025, with the firm’s price target at $4. Piper Sandler coverage for the Replimune Group Inc (REPL) stock in a research note released on July 22, 2025 offered a Neutral rating with a price target of $3. Leerink Partners was of a view on July 22, 2025 that the stock is Market Perform, while JP Morgan gave the stock Neutral rating on July 22, 2025, issuing a price target of $9. Cantor Fitzgerald on their part issued Overweight rating on June 20, 2025.
